News headlines about Aptevo Therapeutics (NASDAQ:APVO) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aptevo Therapeutics earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.5004039284857 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of Aptevo Therapeutics (NASDAQ:APVO) traded down $0.07 during midday trading on Friday, hitting $4.40. 131,918 shares of the stock traded hands, compared to its average volume of 159,151. Aptevo Therapeutics has a 52-week low of $1.15 and a 52-week high of $4.85. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.67 and a current ratio of 7.76.
Several research analysts have recently issued reports on the stock. ValuEngine downgraded shares of Aptevo Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 10th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $6.00 target price on shares of Aptevo Therapeutics in a research note on Thursday, October 5th.
In other news, VP Randy Joe Maddux bought 25,000 shares of the company’s stock in a transaction dated Wednesday, November 15th. The shares were purchased at an average price of $2.76 per share, for a total transaction of $69,000.00. Following the completion of the purchase, the vice president now owns 25,000 shares in the company, valued at approximately $69,000. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 15.60% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Aptevo Therapeutics (APVO) Share Price” was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.thelincolnianonline.com/2018/01/14/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-aptevo-therapeutics-apvo-share-price.html.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.